Table 1.
AICy | Lymphoproliferative Disorder | Frequency of AICy | Key Findings | References |
---|---|---|---|---|
AIHA | CLL | 7 to 15% | The commonest AICy correlating with advanced disease and high biologic risk (del 11q, del17p, unmutated IGHV) | [1,11] |
NHL | 2 to 50% | Frequency is maximal in angioimmunoblastic T-cell lymphoma and in marginal zone lymphoma | [5,12] | |
HL | 0.2% | Very rare association, but may increase after HSCT or therapy with CPIs. | [4,5,13,14] | |
LGLL | Case reports | May be concomitant, precede or follow LGL diagnosis; may be concomitant to ITP and AIN and be multi-refractory (even require splenectomy) | [15] | |
CD | Case reports to 6% | May revert after anti-IL6 therapy with tocilizumab | [16] | |
ALL | Case reports | Mainly B-ALL in the pediatric setting and post-HSCT | [17] | |
MM | Case reports | May rarely complicate MM and also precede the diagnosis. | [18] | |
ITP | CLL | 1 to 5% | Even in association with AIHA (ES). Difficult to distinguish from infiltrative cytopenia; response to steroids and IVIG may confirm the diagnosis | [11] |
NHL | Case reports | Mainly in Waldenström macroglobulinemia and marginal zone NHL; may also follow fludarabine treatment and HSCT. | [12] | |
HL | 0.2 to 1% | May precede or follow HL diagnosis and be observed even after remission; ITP risk may increase after HSCT or CPIs. | [13,14,19] | |
LGLL | 1 to 20% | May respond to steroids, IVIG and cytotoxic immunosuppressants used for LGL | [20] | |
CD | Case reports | Case reports of ITP and ES during CD progression, may respond to rituximab or be refractory | [21] | |
ALL | Case reports | Mostly during chemotherapy. Some require more than 3 lines including splenectomy | [22] | |
MM | Case reports | MM may be complicated by ITP and ES; lenalidomide may increase the risk. | [23,24] | |
AA/PRCA/AIN | CLL | <1% | AIN has been reported in only 3 out of 1750 patients (0.17%); anti-neutrophil autoantibodies may be positive | [11] |
NHL | Case reports | Up to 21 cases of PRCA and rarely AA reported; may develop at onset, during remission, or after chemotherapy and/or HSCT; may be associated with EBV infection and AIHA | [12] | |
HL | Case reports | 16 patients reported in literature. Case reports of AIN, even years after remission, successfully treated with IVIG | [14,25] | |
LGLL | Case reports | Three patients with concomitant amegakaryocytic thrombocytopenia and PRCA and 1 with concomitant AIHA, ITP and AIN | [26] | |
ALL | Case reports | Two patients with T-ALL developed PRCA, possibly associated with ALL therapy; 1 patient with T-lymphoblastic lymphoma presented as AA and hypercalcemia | [27] | |
MM | Case report | Association of AIN and anti-thyroid autoantibodies | [28] |
AIHA autoimmune hemolytic anemia, ITP immune thrombocytopenia, AA aplastic anemia, PRCA pure red cell aplasia, AIN autoimmune neutropenia, CLL chronic lymphocytic leukemia, NHL non-Hodgkin lymphoma, HL Hodgkin lymphoma, LGLL large granular lymphocyte leukemia, CD Castleman disease, ALL acute lymphoblastic leukemia, MM multiple myeloma; HSCT hematopoietic stem cell transplant; CPIs checkpoint inhibitors, ES, Evans syndrome, IVIG intravenous immunoglobulins, EBV Epstein Barr virus.